Free Historical Stock Data on Forest Labs
Stock Symbol: FRX
|Receive a complete Daily History of this Stock
You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file
in ASCII format within a few hours or ordering.
Product Details | Order
Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products that require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter. Forest's most important United States products consist of branded ethical drug specialties marketed directly, or detailed, to physicians by the Company's Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare and Forest Specialty Sales sales forces. Such products include Celexa, Forest's SSRI for the treatment of depression; the respiratory products Aerobid and Aerochamber; Tiazac, Forest's once-daily diltiazem for the treatment of hypertension and angina, and Infasurf, a lung surfactant for the treatment and prevention of respiratory distress syndrome in premature infants.
FRX develops, manufactures and sells both branded and generic forms of ethical drug products which require a physicians prescription, as well as non-prescription pharmaceutical products sold over-the counter. For the three months ended 6/30/02, revenues rose 33% to $478.8 million. Net income increased 67% to $123.8 million. Revenues reflect increased sales and higher average selling prices for Celexa. Net income also reflects improved plant utilization.